Legislative, educational, policy and other interventions targeting physicians' interaction with pharmaceutical companies: A systematic review

BMJ Open

Volumn 4, Issue 7, 2014, Pages

  Alkhaled, Lina ^a   Kahale, Lara ^a   Nass, Hala ^b   Brax, Hneine ^c   Fadlallah, Racha ^a   Badr, Kamal ^a   Akl, Elie A ^a,d,e  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b DAMASCUS UNIVERSITY   (Syrian Arab Republic)

^c SAINT JOSEPH UNIVERSITY   (Lebanon)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; DRUG LEGISLATION; GENERAL PRACTICE; HEALTH CARE POLICY; HUMAN; MEDICAL EDUCATION; OBSERVATIONAL STUDY; PHYSICIAN; POSTGRADUATE EDUCATION; PRACTICE GUIDELINE; PRESCRIPTION; PROFESSIONAL PRACTICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; EDUCATION; LEGISLATION AND JURISPRUDENCE; POLICY; PUBLIC RELATIONS;

DRUG INDUSTRY; INTERPROFESSIONAL RELATIONS; PHYSICIANS; POLICY;

EID: 84903643797     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-004880     Document Type: Review

References (16)

1. Tong KL, Lien CY. Do pharmaceutical representatives misuse their drug samples? Can Fam Physician 1995;41:1363-6.
2. DataMonitor. Personalized physician marketing: Using physician profiling to maximize returns. New York, NY, 2001. http://www.datamonitor.com http://www.informabusinessinformation.com/About-Us/
3. Othman N, Vitry AI, Roughead EE, et al. Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia. BMC Public Health 2010;10:743.
4. Dixon D, Takhar J, Macnab J, et al. Controlling quality in CME/CPD by measuring and illuminating bias. J Contin Educ Health Prof 2011;31:109-16.
5. Grande D. Limiting the influence of pharmaceutical industry gifts on physicians: self-regulation or government intervention? J Gen Intern Med 2010;25:79-83.
6. Roughead EE, Harvey KJ, Gilbert AL. Commercial detailing techniques used by pharmaceutical representatives to influence prescribing. Aust N Z J Med 1998;28:306-10. (Pubitemid 28322354)
7. Silverman E. Everything you need to know about the Sunshine Act. BMJ 2013;347:f4704.
8. Carroll AE, Vreeman RC, Buddenbaum J, et al. To what extent do educational interventions impact medical trainees' attitudes and behaviors regarding industry-trainee and industry-physician relationships? Pediatrics 2007;120:e1528-35.
9. Guyatt G, Oxman AD, Akl EA, et al . GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-94.
10. Boltri JM, Gordon ER, Vogel RL. Effect of antihypertensive samples on physician prescribing patterns. Fam Med 2002;34:729-31. (Pubitemid 35340407)
11. Hartung DM, Evans D, Haxby DG, et al. Effect of drug sample removal on prescribing in a family practice clinic. Ann Fam Med 2010;8:402-9.
12. Spurling G, Mansfield P. General practitioners and pharmaceutical sales representatives: quality improvement research. Qual Saf Health Care 2007;16:266-70. (Pubitemid 47262397)
13. Freemantle N, Johnson R, Dennis J, et al. Sleeping with the enemy? A randomized controlled trial of a collaborative health authority/industry intervention to influence prescribing practice. Br J Clin Pharmacol 2000;49:174-9. (Pubitemid 30068296)
14. Wikepedia. NHS strategic health authority. Secondary NHS strategic health authority. http://en.wikipedia.org/wiki/NHS-strategic-health-authority
15. Norris P, Herxheimer A, Lexchin J, et al. Drug promotion - what we know, what we have yet to learn - reviews of materials in the WHO/HAI database on drug promotion. 2005. EDM Research Series No. 032.
16. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283:373-80. (Pubitemid 30051756)